| Endpoint | Volumetric parameters | Factor | No. of studies | Heterogeneity test (I2, ) | Effect model | HR | 95% CI of HR | Conclusion |
| PFS | MTV | Region | | | | | | | | | Asian | 3 | 0.0, 0.606 | Fixed | 3.22 | 1.84, 5.62 | Significant | | | European | 1 | — | — | 3.29 | 1.27, 8.52 | Significant | | | American | 1 | | | 1.66 | 0.44, 8.1 | Insignificant | | | Cut-off method | | | | | | | | | ROC | 1 | — | — | 4.07 | 1.25, 13.25 | Significant | | | Others | 4 | 0.0, 0.703 | Fixed | 2.89 | 1.75, 4.75 | Significant | | | Analysis method | | | | | | | | | Multivariate analysis | 2 | 0.0, 0.370 | Fixed | 3.01 | 1.59, 5.67 | Significant | | | Univariate analysis | 3 | 0.0, 0.644 | Fixed | 3.08 | 1.58, 5.99 | Significant |
| OS | TLG | Region | | | | | | | | | Asian | 4 | 0.0, 0.455 | Fixed | 2.17 | 1.46, 3.23 | Significant | | | American | 1 | — | — | 2.13 | 0.75, 6.04 | Insignificant | | | Cut-off method | | | | | | | | | ROC | 1 | — | — | 3.73 | 0.84, 16.51 | Insignificant | | | Others | 4 | 0.0, 0.559 | Fixed | 2.09 | 1.42, 3.07 | Significant | | | Analysis method | | | | | | | | | Multivariate analysis | 3 | 0.0, 0.890 | Fixed | 2.85 | 1.68, 4.83 | Significant | | | Univariate analysis | 2 | 0.0, 0.577 | Fixed | 1.65 | 0.97, 2.79 | Insignificant |
|
|
HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival; MTV, metabolic tumor volume; TLG, total lesion glycolysis; ROC, receiver operating characteristic.
|